Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 1, 2026, 5:33 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1393–1416 of 1,709 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Human Immunodeficiency Virus Infection (HIV) Clear all
Completed Not applicable Interventional

A Study of Itraconazole in the Prevention of Histoplasmosis, a Fungal Infection, in HIV-Infected Patients

NCT00002438
View directory record Official record
Conditions
HIV Infections, Histoplasmosis
Interventions
Itraconazole
Drug
Lead sponsor
Janssen, LP
Industry
Eligibility
13 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
7
States / cities
Indianapolis, Indiana • Kansas City, Missouri • Memphis, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Nov 1, 2026, 5:33 AM EST
Completed No phase listed Observational Accepts healthy volunteers Results available

The Compartmental Biology of HIV in the Male Genital Tract

NCT02638493
View directory record Official record
Conditions
Human Immunodeficiency Virus, Virus Shedding
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 60 Years · Male only
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 24, 2017 · Synced Nov 1, 2026, 5:33 AM EST
Completed No phase listed Observational Accepts healthy volunteers

Long-Term Effects of HIV Exposure and Infection in Children

NCT00006304
View directory record Official record
Conditions
HIV Infections, HIV Seronegativity
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
24 Hours to 21 Years
Enrollment
4,150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2002
U.S. locations
89
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2013 · Synced Nov 1, 2026, 5:33 AM EST
Completed No phase listed Observational Accepts healthy volunteers

An Observational Study of Long-term Outcomes of HIV-1 Infection in Persons Who Become HIV-1 Infected After Enrollment in HIV-1 Vaccine Trials

NCT03337906
View directory record Official record
Conditions
HIV Infections
Interventions
Observation
Other
Lead sponsor
HIV Vaccine Trials Network
Network
Eligibility
18 Years and older
Enrollment
209 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2016
U.S. locations
13
States / cities
Birmingham, Alabama • San Francisco, California • Decatur, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2022 · Synced Nov 1, 2026, 5:33 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Two-part Study to Compare a Tablet and Capsule Formulation of GSK2838232 With and Without Food, and to Assess the Safety and Drug Levels of Repeated Once-daily Doses of GSK2838232 Without Ritonavir

NCT03234036
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus, HIV Infections
Interventions
GSK2838232 100 mg tablet, GSK2838232 50 mg capsule, Ritonavir 100 mg tablets, Placebo for GSK2838232 tablets
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 28, 2020 · Synced Nov 1, 2026, 5:33 AM EST
Not yet recruiting Not applicable Interventional

Addressing Barriers to Anti-hypertensive Medication Adherence Among PLWH Who Have Achieved Viral Suppression

NCT05459077
View directory record Official record
Conditions
Hypertension, HIV-1-infection
Interventions
Hypertension control through education and monitoring
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Nov 1, 2026, 5:33 AM EST
Completed Not applicable Interventional

The Safety and Effectiveness of Clarithromycin Plus Ethambutol Used With or Without Clofazimine in the Treatment of MAC in Patients With AIDS

NCT00002331
View directory record Official record
Conditions
Mycobacterium Avium-intracellular Infection, HIV Infections
Interventions
Ethambutol hydrochloride, Clarithromycin, Clofazimine
Drug
Lead sponsor
Abbott
Industry
Eligibility
13 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 1995
U.S. locations
17
States / cities
Los Angeles, California • Sacramento, California • San Francisco, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2015 · Synced Nov 1, 2026, 5:33 AM EST
Completed Not applicable Interventional

The Antiviral Efficacy of Concurrent Zidovudine and 2',3'-Dideoxyinosine or 2',3'-Dideoxycytidine in Patients With Human Immunodeficiency Virus Disease

NCT00002001
View directory record Official record
Conditions
HIV Infections
Interventions
Zidovudine, Zalcitabine, Didanosine
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
13 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
3
States / cities
Denver, Colorado • Washington D.C., District of Columbia • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Nov 1, 2026, 5:33 AM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effectiveness of an Online Prevention Program in Reducing the Risk of STD Infection in Young Adults

NCT00255944
View directory record Official record
Conditions
HIV Infections, Sexually Transmitted Diseases
Interventions
Youthnet Internet-based program, Control Internet based program
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 25 Years
Enrollment
2,622 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 5, 2020 · Synced Nov 1, 2026, 5:33 AM EST
Terminated Phase 1 Interventional

Safety and Tolerability of Z-100 in Patients With Early HIV Infection

NCT00016692
View directory record Official record
Conditions
HIV Infections
Interventions
Z-100
Drug
Lead sponsor
Zeria Pharmaceutical
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
3
States / cities
San Francisco, California • Chicago, Illinois • Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 27, 2006 · Synced Nov 1, 2026, 5:33 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Suspension Injection of Investigational Capsid Inhibitors Compared to Placebo in Healthy Adults

NCT06012136
View directory record Official record
Conditions
HIV Infections
Interventions
VH4004280, Placebo, VH4011499
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 55 Years
Enrollment
85 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
2
States / cities
Las Vegas, Nevada • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Nov 1, 2026, 5:33 AM EST
Completed Phase 2 Interventional

An Open-Label Treatment Protocol to Provide Continued Elvucitabine Treatment

NCT00675844
View directory record Official record
Conditions
HIV Infections
Interventions
Elvucitabine
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
5
States / cities
Orlando, Florida • Pensacola, Florida • Newark, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Nov 1, 2026, 5:33 AM EST
Terminated Phase 1 Interventional Results available

Pharmacokinetics and Safety of SAR441236

NCT03705169
View directory record Official record
Conditions
HIV-1-infection
Interventions
SAR441236, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
23
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2024 · Synced Nov 1, 2026, 5:33 AM EST
Completed Phase 3 Interventional Results available

Infrared Coagulator Ablation or Observation in Preventing Anal Cancer in HIV-Positive Patients With Anal Neoplasia

NCT01164722
View directory record Official record
Conditions
Anal Cancer, Neoplasm of Uncertain Malignant Potential, Nonneoplastic Condition, Precancerous Condition
Interventions
clinical observation, infrared photocoagulation therapy
Other · Device
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
27 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
7
States / cities
Los Angeles, California • San Francisco, California • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2020 · Synced Nov 1, 2026, 5:33 AM EST
Completed Not applicable Interventional

An Evaluation of Pentoxifylline in HIV-Positive Persons With Symptomatic HIV Infection and a Karnofsky Score > 40 Percent and < 100 Percent

NCT00002091
View directory record Official record
Conditions
HIV Infections
Interventions
Pentoxifylline
Drug
Lead sponsor
Community Research Initiative of New England
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Brookline, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Nov 1, 2026, 5:33 AM EST
Terminated No phase listed Observational

Investigation of The Effect of Cenicriviroc (CVC) Plus FTC/TDF on Cardiovascular Disease Risk Factors

NCT01474954
View directory record Official record
Conditions
HIV Infection
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 12, 2015 · Synced Nov 1, 2026, 5:33 AM EST
Completed Phase 2 Interventional

An Open Label Trial of TMC114/RTV in HIV-1 Infected, Treatment-experienced Subjects.

NCT00081588
View directory record Official record
Conditions
HIV Infection
Interventions
TMC114
Drug
Lead sponsor
Tibotec Pharmaceuticals, Ireland
Industry
Eligibility
18 Years and older
Enrollment
555 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
26
States / cities
Birmingham, Alabama • Beverly Hills, California • La Jolla, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2014 · Synced Nov 1, 2026, 5:33 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Hepatitis B Virus (HBV) Prevention for Homeless at Risk for HBV/Hepatitis C Virus (HCV)/HIV

NCT00926146
View directory record Official record
Conditions
Hepatitis B, Hepatitis C, HIV, HIV Infections
Interventions
NCMIT, SCMIT
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 39 Years · Male only
Enrollment
451 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 30, 2017 · Synced Nov 1, 2026, 5:33 AM EST
Terminated Phase 2 Interventional

A Phase II Trial of COL-3 in Patients With HIV Related Kaposi's Sarcoma

NCT00020683
View directory record Official record
Conditions
AIDS-related Kaposi Sarcoma, HIV Infection
Interventions
incyclinide, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 18, 2018 · Synced Nov 1, 2026, 5:33 AM EST
Completed Not applicable Interventional

Effectiveness of an Integrated Treatment to Address Smoking Cessation and Anxiety/ Depression in People Living With HIV

NCT03904186
View directory record Official record
Conditions
Human Immunodeficiency Virus, Smoking Cessation, Smoking, Cigarette, Smoking, Anxiety, Depression, Nicotine Dependence
Interventions
QUIT, Time-Matched Control (TM)
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 79 Years
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
3
States / cities
Boston, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Nov 1, 2026, 5:33 AM EST
Completed Phase 3 Interventional Results available

A Study to Evaluate Efficacy and Safety of Cabotegravir (CAB) Long Acting (LA) Plus (+) Rilpivirine (RPV) LA Versus BIKTARVY® (BIK) in Participants With Human Immunodeficiency Virus (HIV)-1 Who Are Virologically Suppressed

NCT04542070
View directory record Official record
Conditions
HIV Infections
Interventions
Cabotegravir Tablets, Cabotegravir Injectable Suspension (CAB LA), Rilpivirine Tablets, Rilpivirine Injectable Suspension (RPV LA), BIKTARVY Tablets (BIK)
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
687 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
41
States / cities
Bakersfield, California • Beverly Hills, California • Los Angeles, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2024 · Synced Nov 1, 2026, 5:33 AM EST
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Botswana TDF/FTC Oral HIV Prophylaxis Trial

NCT00448669
View directory record Official record
Conditions
HIV Infections
Interventions
Tenofovir Disoproxil Fumarate 300 mg + Emtricitabine 200 mg, Placebo Oral Tablet
Drug
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
18 Years to 39 Years
Enrollment
1,219 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Nov 1, 2026, 5:33 AM EST
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Oral ISL QM as PrEP in Cisgender Women at High Risk for HIV-1 Infection (MK-8591-022)

NCT04644029
View directory record Official record
Conditions
HIV-I, Human Immunodeficiency Virus Type 1, Prophylaxis
Interventions
Islatravir, Placebo to FTC/TDF, FTC/TDF, Placebo to ISL
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
16 Years to 45 Years · Female only
Enrollment
730 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
13
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Nov 1, 2026, 5:33 AM EST
Recruiting Not applicable Interventional Accepts healthy volunteers

Ending the Epidemic Interventions in the Dental Setting - UH3

NCT06890988
View directory record Official record
Conditions
HIV-1-infection
Interventions
Care Navigator, Multicomponent HIV Service Package
Other
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
128 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
3
States / cities
New York, New York • Queens, New York
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Nov 1, 2026, 5:33 AM EST